tirzepatide cvot trial SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

Half of Americans think weight-loss medications like Ozempic are only for the wealthy

Curious about microdosing GLP-1s

Designed to help curb appetite, improve blood sugar control, and promote []

Incline and decline pressing, rows, step-ups, Bulgarian split squats, and a long list of accessory movements all become available

Pain Scores: Treatment resulted in a 75.8% reduction in WOMAC pain scores compared to baseline

This graph diagrams utilization, unit cost, and cost as a percent of overall medical cost trend: note that by the middle of 2023, GLP-1 drug costs for Group health plan members comprised 13.6% of a major pharmacy benefit management (PBM) company, shown in the third bar